A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles

Ng, Ernest Hung Yu; Miao, Benyu; Cheung, Wai‐Lung; Ho, Pak‐Chung

doi:10.1016/s0301-2115(03)00156-8

Cited by 31 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three of the trials provided an adequate randomization mode (11,14,17), and four an adequate mode for allocation concealment (11,12,16,17). One of the trials was single blinded (assessor blinded) (16), and two of the trials recruited patients from more than one center (11,16).…”

Section: Methodologic Quality Of Eligible Trialsmentioning

confidence: 99%

“…Four trials compared 90 mg once or twice daily daily dosage of vaginal P gel versus 600 mg daily vaginal P capsules (utrogestan or utrogest) (11)(12)(13)(14), one trial versus 200, 400, or 600 mg utrogestan and 400 mg daily vaginal P pessaries (cyclogest) (15), one versus 100 or 200 mg daily vaginal P inserts (endometrin) (16), and one versus 800 mg daily vaginal P pessaries (cyclogest) (17). The median ages of patients enrolled ranged from 30.1 to 34.8 years Table 1.…”

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

“…Six of the trials used GnRH agonist protocol for IVF/ICSI cycles (11)(12)(13)(15)(16)(17) and one either GnRH agonist or antagonist (14). In the majority of the trials, ovarian stimulation protocols included either hMG or rFSH, with the exception of one trial in which the authors did not specify the exact controlled ovarian hyperstimulation protocol used (15).…”

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

“…Finally, the day of the initiation of LPS was the day of the embryo transfer in three of the trials (11,15,17), 1 day after the oocyte retrieval in two trials (12,16), and 1 day before ET in one trial (14).…”

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

See 3 more Smart Citations

Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis

Polyzos

Messini

Papanikolaou

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

Section: Methodologic Quality Of Eligible Trialsmentioning

confidence: 99%

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

Section: Characteristics Of Eligible Trialsmentioning

confidence: 99%

See 2 more Smart Citations

Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis

Polyzos

Messini

Papanikolaou

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

“…Another study evaluated side effects and patient inconvenience of progesterone 400 mg vaginal pessaries administered twice daily versus 8% vaginal gel once daily. Perineal irritation was reported by about 20% of patients in each group, and this study also reported inconvenience of administration, leaking and interference with coitus [16]. …”

Section: Discussionmentioning

confidence: 94%

Observational Study of the Local Tolerability of Injectable Progesterone Microspheres

Bernardo-Escudero

Cortés-Bonilla²,

Alonso-Campero³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: As intramuscular progesterone administration is associated with local intolerance, the purpose of this work was to determine the local tolerability of a new progesterone microsphere suspension, administered by intramuscular injection. Methods: An observational, longitudinal, prospective, analytical, multicenter, active pharmacovigilance study was conducted. Two hundred and seven progesterone microsphere administrations were evaluated. Patients evaluated pain, burning sensation, pruritus and dysesthesia. Physicians evaluated erythema, pallor, petechia, ecchymosis, bleeding, edema, induration, abscess, macule, papule, vesicle and pustule. Local tolerability was evaluated using a visual analog scale (100-mm line) on the day of administration, and subsequently on days 3 and 7. Local symptoms were evaluated by patients and local signs by the attending physicians. Results: On the day of application, 68.4% of the administered doses were associated with ‘absent’ or ‘mild’ pain, rising to 91.2% on the 7th day; 83.0% of doses were associated with ‘absence’ of or a ‘mild’ burning sensation on the day of administration, rising to 99.5% on day 7. On administration day, 13.2% reported ‘mild’ erythema and 1.0% ‘moderate’ erythema, and 3.9% of doses had ‘mild’ induration and 0.5% ‘moderate’ induration, which increased to 16.6 and 2.9% on day 3, respectively. The values for pallor, ecchymosis, bleeding, edema and pustule were lower than 10 mm (of 100 mm) on the application day and behaved similarly in subsequent days. There were no reports of petechia, abscess, macule, papule or vesicle with the dose application. Conclusions: Progesterone microspheres were well tolerated without serious or unexpected adverse effects.

show abstract

Luteal phase support in assisted reproduction cycles

Daya

Gunby

2004

Cochrane Database of Systematic Reviews

132

View full text Add to dashboard Cite

A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles

Cited by 31 publications

References 24 publications

Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis

Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis

Observational Study of the Local Tolerability of Injectable Progesterone Microspheres

Luteal phase support in assisted reproduction cycles

Contact Info

Product

Resources

About